Buparlisib experimental drug molecule

Buparlisib experimental drug molecule

C028/8025 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 50.1MB

Downloadable file size: 1.6MB

Price image Pricing

Please login to use the price calculator


Caption: Buparlisib. Molecular model of the experimental cancer drug Buparlisib. Buparlisib is a phosphoinositide 3-kinase inhibitor (PI3K inhibitor) undergoing clinical trials for treatment of advanced endocrine-resistant breast cancer. PI3K inhibitors are a class of drugs that function by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are important in signalling pathways for many cellular functions. These include growth control, metabolism and translation of genes into proteins. Inhibition of any of these processes can result in tumour suppression. Atoms are represented as spheres and are colour-coded: carbon (grey), hydrogen (white), nitrogen (blue), oxygen (red) and iron (green).

Release details: Model release not required. Property release not required.

Keywords: 1, anti-cancer, artwork, ball and stick, ball-and-stick, biochemical, biochemistry, biologic, biological, biology, black background, breast cancer, buparlisib, cancer, chemical, chemistry, chemotherapy, clinical trial, cut out, cut outs, cut-out, cut-outs, cutout, cutouts, digitally generated, drug, experimental, graphic, healthcare, illustration, inhibition, investigation, investigational, medical, medication, medicine, model, molecular, molecule, new, no one, no-one, nobody, oncology, pathway, pharmaceutical, pharmaceutics, pharmacological, pharmacology, phosphoinositide 3-kinase inhibitor, pi3k inhibitor, plain background, research, research and development, signalling, structure, targeted, test, testing, therapy, treatment, trial

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.